Outcomes and risk assessment in pulmonary veno-occlusive disease - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue ERJ Open Research Année : 2024

Outcomes and risk assessment in pulmonary veno-occlusive disease

Athénaïs Boucly
Sabina Solinas
  • Fonction : Auteur
Antoine Beurnier
Xavier Jaïs
Sophia Keddache
  • Fonction : Auteur
Mélanie Eyries
Andrei Seferian
Mitja Jevnikar
Anne Roche
  • Fonction : Auteur
Sophie Bulifon
  • Fonction : Auteur
Ari Chaouat
Vincent Cottin
Laurent Bertoletti
Laurent Savale
Marc Humbert
Olivier Sitbon
David Montani

Résumé

Introduction Pulmonary veno-occlusive disease (PVOD) is a rare and severe subtype of pulmonary arterial hypertension (PAH). Although European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines advise assessing PAH severity at baseline and during follow-up, no existing risk assessment methods have been validated for PVOD. This study aimed to identify prognostic factors, examine the impact of treatment strategies and evaluate risk assessment methods for PVOD patients. Methods The study analysed all incident PVOD patients included in the French Pulmonary Hypertension Registry between 2006 and 2021. Survival was assessed based on initial treatment strategy and risk status and compared to a matched (age, sex, pulmonary vascular resistance) PAH group. Six risk assessment methods (number of four low-risk and three noninvasive low-risk variables, ESC/ERS guidelines three-strata and four-strata models, REVEAL 2.0 and Lite 2) were applied at baseline and early follow-up, and their accuracy was compared using Harrell's c-statistic. Results Among the 327 included PVOD patients, survival rates at 1, 3 and 5 years were 86%, 50% and 27%, respectively. Multivariate analysis showed that only 6-min walk distance was associated with survival, with no significant difference based on initial treatment strategy. All six risk assessment methods could discriminate mortality risk, and the ESC/ERS four-strata model was the most accurate at both baseline and follow-up (C-index 0.64 and 0.74). PVOD survival rates were consistently lower than PAH when comparing baseline risk status using the ESC/ERS four-strata model. Conclusion PVOD is associated with poor outcomes, and initial treatment strategies do not significantly affect survival. Risk assessment methods can be useful in predicting survival for PVOD patients.
Fichier principal
Vignette du fichier
2024 Boucly et al., Outcomes and risk.pdf (736.21 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04397755 , version 1 (16-01-2024)

Identifiants

Citer

Athénaïs Boucly, Sabina Solinas, Antoine Beurnier, Xavier Jaïs, Sophia Keddache, et al.. Outcomes and risk assessment in pulmonary veno-occlusive disease. ERJ Open Research, 2024, 10 (1), pp.00612-2023. ⟨10.1183/23120541.00612-2023⟩. ⟨hal-04397755⟩
14 Consultations
8 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More